October 11, 2023

Thermedical Awarded $3 Million NIH Grant to Study Promising Treatment for Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

Thermedical, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced it has received $3 million in grant funding (1R44HL169112) from the National Heart, Lung, and Blood Institute, a part of the National Institutes of Health, to fund its FDA-approved clinical trial at seven centers in the U.S. and Canada using the SERF Ablation System with the Durablate Catheter to treat ventricular tachycardia (VT). VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.

Thermedical is a privately held company founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni Michael G. Curley, Ph.D., and Patrick S. Hamilton, Ph.D., based in Waltham, Mass. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the company has developed thermal-ablation systems to treat ventricular tachycardia (VT) and solid tumors.